However, our findings have demonstrated that TM4SF4 expression is more restricted compared with other more commonly investigated HCC surface therapeutic targets (e.g., GPC3 and CD147) which are highly expressed in tissues critical for survival such as the lungs and brain. This evidence concerns the gene GPC3 and hepatocellular carcinoma.